The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the ...

Opella reaches study milestone for CialisParis, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

Menopause is a chapter in women’s lives that brings a myriad of sometimes debilitating medical issues that can last for more ...

The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from cancer and type 2 diabetes to asthma.

List of drugs account for $41 billion in annual Medicare spending, the Biden administration said.

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

The palace made the rare decision to release two health announcements, marking the start of a year that would prove to be ...

Spruce Point Capital warns of Procept BioRobotics' overstated market potential and growth claims, citing niche product ...

The global BPH treatment market is expected to grow from USD 33,031.10 million in 2024 to USD 47,045.80 million by 2034, at a ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Manipal Hospitals Sarjapur Road hosted a session on HoLEP for Benign Prostatic Hyperplasia. This innovative technique, led by ...